Mineralys Therapeutics, Inc. MLYS Payments Of Stock Issuance Costs
Payments Of Stock Issuance Costs at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s payments of stock issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s payments of stock issuance costs?
- Mineralys Therapeutics, Inc. (MLYS) reported payments of stock issuance costs of $1K in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s payments of stock issuance costs changed year-over-year?
- Mineralys Therapeutics, Inc.'s payments of stock issuance costs decreased by 90.0% year-over-year, from $10K to $1K.
- What does payments of stock issuance costs mean?
- This represents the direct cash outflows incurred to facilitate the issuance of equity securities, such as underwriting fees, legal expenses, and registration costs. These costs are typically deducted from the gross proceeds of a capital raise. Tracking these payments is essential for evaluating the net efficiency of a company's equity financing activities.